Johnson & Johnson, no stop to single-dose vaccine. Locatelli: “Fewer adverse events”

Johnson & Johnson, no stop to single-dose vaccine. Locatelli: “Fewer adverse events”
Johnson & Johnson, no stop to single-dose vaccine. Locatelli: “Fewer adverse events”

The CTS recommendation on AstraZeneca will not also affect Johnson & Johnson. The coordinator of the CTS, Franco Locatelli, during the press conference to update the vaccination campaign, clarified: “It is true that J&J is based on a human adenoviral vaccine compared to the chimpanzee vaccine of AstraZeneca, it is true that there is some report of thrombotic phenomena in an unusual location, however there is a lower frequency and we have a significantly lower number of subjects who received this vaccine, around 1 million and 100 thousand doses. Providing these elements to politics underlining known information and areas of uncertainty, with the accumulation of evidence will help in making choices ».

Source

Johnson Johnson stop singledose vaccine Locatelli adverse events

PREV Euro2020, Austria beats Shevchenko and challenges Italy. Fly Holland
NEXT Austria, coach Foda: "Against Italy it seems an impossible match, but in football …" – All Juve